Publications by authors named "Collin Dean"
Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025).
Am J Health Syst Pharm
November 2024
Article Synopsis
- AJHP is posting accepted manuscripts online quickly after peer review, but these are not final versions and will be updated later.
- The article aims to assist health-system pharmacists by providing updates on new drug approvals that can affect clinical practices and resource management.
- A selection of 51 potential new drugs awaiting FDA approval is discussed, highlighting significant developments in treatments for rare diseases, cancers, and other conditions expected between late 2024 and mid-2025.
Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025).
Am J Health Syst Pharm
November 2024
Article Synopsis
- AJHP is posting accepted manuscripts online promptly to speed up publication, even before final formatting and author proofing are completed.
- The article highlights the essential role of health-system pharmacists in managing drug formularies and resources, focusing on upcoming drug approvals that could impact clinical practices.
- Anticipated drug approvals include new treatments for various cancers and rare diseases, with several innovative therapies and delivery methods under review by the FDA for the period of late 2024 to mid-2025.
Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025).
Am J Health Syst Pharm
August 2024
Article Synopsis
- Health-system pharmacists are vital for managing drug formularies and clinical programs, and this article provides updates on upcoming drug approvals to aid their work.
- The article reviews drug approvals expected between Q2 2024 and Q1 2025, focusing on those that may significantly impact healthcare settings and are awaiting FDA approval.
- New therapies are being developed for cancers and rare diseases, alongside drugs addressing conditions like diabetes and chronic obstructive pulmonary disease.